EDITAS MEDICINE INC.

Editas Medicine Announces Third Quarter 2021 Results and Business Updates

08 Nov 2021 06:00:01 By Nasdaq GlobeNewswire

Editas Medicine to Present Data Demonstrating Progress Towards Transformative Gene Editing Medicines for the Treatment of Hemoglobinopathies and Cancer at the ASH Annual Meeting and Exposition

04 Nov 2021 08:02:00 By Nasdaq GlobeNewswire

Editas Medicine Names Bernadette Connaughton to Board of Directors

28 Oct 2021 08:00:02 By Nasdaq GlobeNewswire

Editas Medicine to Host Conference Call Discussing Third Quarter 2021 Results and Corporate Update

25 Oct 2021 15:01:00 By Nasdaq GlobeNewswire

Clinical Data from Editas Medicine’s Ongoing Phase 1/2 BRILLIANCE Clinical Trial of EDIT-101 for LCA10 to be Presented at the European Society of Gene and Cell Therapy Annual Congress

20 Oct 2021 08:00:01 By Nasdaq GlobeNewswire

Editas Medicine to Present Preclinical Data on Novel Engineered iPSC Derived NK Cells for the Treatment of Cancer at the Society for Immunotherapy of Cancer 36th Annual Meeting

07 Oct 2021 07:00:01 By Nasdaq GlobeNewswire

Editas Medicine to Present at Chardan’s 5th Annual Genetic Medicines Conference

30 Sep 2021 07:00:00 By Nasdaq GlobeNewswire

Editas Medicine Announces Positive Initial Clinical Data from Ongoing Phase 1/2 BRILLIANCE Clinical Trial of EDIT-101 for LCA10

29 Sep 2021 08:00:01 By Nasdaq GlobeNewswire

Editas Medicine Names Emma Reeve to Board of Directors

08 Sep 2021 08:00:01 By Nasdaq GlobeNewswire

Initial Clinical Data from Editas Medicine’s BRILLIANCE Clinical Trial of EDIT-101 for LCA10 to be Presented at the International Symposium on Retinal Degeneration in September

07 Sep 2021 15:00:00 By Nasdaq GlobeNewswire

Editas Medicine to Participate in Upcoming Investor Conferences

02 Sep 2021 07:00:01 By Nasdaq GlobeNewswire

Editas Medicine Presents Data on New SLEEK Gene Editing Technology at Cold Spring Harbor Laboratory’s Genome Engineering: CRISPR Frontiers Meeting

20 Aug 2021 15:20:00 By Nasdaq GlobeNewswire

Editas Medicine Announces Second Quarter 2021 Results and Business Updates

04 Aug 2021 06:00:01 By Nasdaq GlobeNewswire

Editas Medicine and IDT Announce Publication in Nature Communications of Research Data Supporting the Use of Optimized AsCas12a Nuclease Variant, Alt-R A.s. Cas12a (Cpf1) Ultra, in Researching the Potential of Gene-Edited Cell Medicines

29 Jul 2021 08:00:01 By Nasdaq GlobeNewswire

Editas Medicine to Host Conference Call Discussing Second Quarter 2021 Results and Corporate Update

28 Jul 2021 06:00:01 By Nasdaq GlobeNewswire

Editas Medicine Names Bruce E. Eaton, Ph.D., as Executive Vice President and Chief Business Officer

26 Jul 2021 08:00:00 By Nasdaq GlobeNewswire

Editas Medicine Announces Enrollment of the First Pediatric Cohort in the BRILLIANCE Clinical Trial of EDIT-101 for the Treatment of LCA10 Following IDMC Endorsement

23 Jun 2021 06:00:00 By Nasdaq GlobeNewswire

Editas Medicine Reports Inducement Grants to New Chief Scientific Officer and Chief Regulatory Officer

15 Jun 2021 15:01:00 By Nasdaq GlobeNewswire

Editas Medicine Strengthens Executive Leadership Team to Advance Pipeline and Support Long-term Growth

14 Jun 2021 08:00:01 By Nasdaq GlobeNewswire

Editas Medicine Presents Preclinical Data Supporting the Initiation of the EDIT-301 Phase 1/2 RUBY Clinical Trial for the Treatment of Sickle Cell Disease at the European Hematology Association Congress

11 Jun 2021 05:00:00 By Nasdaq GlobeNewswire